No Data
Express News | NovaBay Pharmaceuticals: Iss Supports Co's Proposals to Authorize Sale of Its Avenova Brand
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of Its Avenova Brand
NovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes
Ascendiant Capital Maintains Buy on NovaBay Pharmaceuticals, Adjusts Price Target To $0.85 (1-35 Reverse Stock Split)
NovaBay GAAP EPS of -$0.60 Misses by $0.30, Revenue of $2.44M Misses by $0.19M
NovaBay Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
No Data
No Data